渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

未开盘 11-21 16:00:00 EST

158.01

+2.01

+1.29%

盘后158.51

+0.50+0.32%

19:59 EST

最高159.10	最低154.74	成交量188.61万
今开157.17	昨收156.00	日振幅2.79%
总市值230.25亿	流通市值229.48亿	总股本1.46亿
成交额2.97亿	换手率1.30%	流通股本1.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":158.01,"timestamp":1732222800000,"preClose":156,"halted":0,"volume":1886119,"hourTrading":{"tag":"盘后","latestPrice":158.51,"preClose":158.01,"latestTime":"19:59 EST","volume":152940,"amount":24166202.45,"timestamp":1732237187291},"delay":0,"floatShares":145229752,"shares":145719340,"eps":11.061496,"marketStatus":"未开盘","marketStatusCode":0,"change":2.01,"latestTime":"11-21 16:00:00 EST","open":157.17,"high":159.1,"low":154.74,"amount":296955498.13059,"amplitude":0.027949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":11.061496,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732266000000},"adr":0,"listingDate":685080000000,"adjPreClose":156,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":157.16,"preClose":156,"latestTime":"09:29 EST","volume":1792,"amount":280860.78719999996,"timestamp":1732199399999},"postHourTrading":{"tag":"盘后","latestPrice":158.51,"preClose":158.01,"latestTime":"19:59 EST","volume":152940,"amount":24166202.45,"timestamp":1732237187291},"volumeRatio":0.973386,"impliedVol":0.3225,"impliedVolPercentile":0.6032},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"2484607758","title":"美股走势-Henry Schein Inc、Palantir Technologies、Uber Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2484607758","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484607758?lang=zh_cn&edition=full","pubTime":"2024-11-19 03:12","pubTimestamp":1731957174,"startTime":"0","endTime":"0","summary":".N美国东部时间13:31，道琼斯工业平均指数.DJI下跌0.12%，报43,394.67点。标普500指数.SPX上涨0.42%，报5894.99点；纳斯达克综合指数.IXIC上涨0.62%，报18798.28点。标准普尔 500 指数.PG.INX百分比涨幅前三名是： ** 超级微型计算机公司SMCI.O，上涨 20.2. ** Henry Schein Inc HSIC.O，上涨 6.9 标普500指数.PL.INX跌幅前三名： ** Amentum Holdings Inc AMTM.N，下跌 9.0. 纽约证券交易所.PG.N百分比涨幅前三名： ** Finance of America Companies Inc FOA.N，上涨 21.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNVD.UK","CMAX","MARA","LUV","PPTA","NTLA","LBRT","GL","NVDU","DCOM","WBD","JBLU","DE","NVDS.UK","TSLA","MSTR","DAL","NVD3.UK","NVDY","2NVD.UK","HIMS","LLY","BIIB","TPR","BBWI","ASB","NVD","NEM","NKE","NVDL","NVD2.UK","TWST","MRNA","CVS","HOOD","HSIC","NVDX","AILE","3NVD.UK","NVDA","UAL","AEO","GAP","HPE","BTBT","MBI","GRNT","VSCO","VLY"],"gpt_icon":1},{"id":"2484670973","title":"BUZZ--美国股票走势-特斯拉公司、帕兰提尔科技公司和超微计算机公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2484670973","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484670973?lang=zh_cn&edition=full","pubTime":"2024-11-19 00:14","pubTimestamp":1731946466,"startTime":"0","endTime":"0","summary":"美国东部时间10:31，道琼斯工业平均指数  下跌0.18%，报43366.20点；标普500指数  上涨0.33%，报5889.99点；纳斯达克综合指数  上涨0.76%，报18821.61点。标准普尔 500 指数  百分比涨幅前三名是：** 超级微型计算机公司  ，上涨 8.5 ** 特斯拉  ，上涨8.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WBD","DE","LBRT","GAP","BBWI","NEM","ASB","DXD",".DJI","AILE","AEO","TSLA","GL","PPTA","NQmain","PLTR","SQQQ","CMAX","UBER","AMTM","DOG","NVDY","AKA","NVDS",".IXIC","BIIB","NTLA",".SPX","HPE","VLY","TPR","DJX","NVDA","VSCO","DCOM","SDOW","MNQmain","TSLL","SNVD.UK","TWST","MBI","CVS"],"gpt_icon":1},{"id":"2484676433","title":"BUZZ--美国股票走势-银矿商、Intellia、Robinhood","url":"https://stock-news.laohu8.com/highlight/detail?id=2484676433","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484676433?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:45","pubTimestamp":1731941147,"startTime":"0","endTime":"0","summary":".N ** 惠普公司HPE.N： BUZZ - 在券商将其评级提升至 \"强烈买入 \"后上涨 nL4N3MP0MD。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP129:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPR","IE00B3M56506.USD","NVDS","2NVD.UK","NEM","HK0000306701.USD","WBD","HIMS","TWST","BK4023","CDE","NTLA","BK4587","NVD","TSLA","NVDX","HOOD","HPE","CMAX","BK4532","CVS","LU2290526834.HKD","HL","LU2491050154.USD","NVDL","LU0278409577.USD","BK4529","SNVD.UK","VLY","DCOM","MRNA","NVDU","3NVD.UK","NVDA","LU1280957306.USD","NVDD","BIIB","ASB","LBRT","LU1366192091.USD","LU1839511570.USD","NVDS.UK","PPTA","NVD3.UK","BTBT","NVDY","NVD2.UK","GL","IE0004445239.USD"],"gpt_icon":1},{"id":"2484137678","title":"BUZZ-Needham下调百健评级至 \"持有\"，原因是阿尔茨海默氏症药物采用缓慢","url":"https://stock-news.laohu8.com/highlight/detail?id=2484137678","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484137678?lang=zh_cn&edition=full","pubTime":"2024-11-18 21:58","pubTimestamp":1731938310,"startTime":"0","endTime":"0","summary":"BUZZ-Needham下调百健评级至 \"持有\"，原因是阿尔茨海默氏症药物采用缓慢11月18日 -  ** 百健BIIB.O股价在收盘前下跌~1%至158.41美元  ** 券商Needham将百健BIIB.O的评级从 \"买入 \"下调至 \"持有\"，理由是明年该股没有 \"有意义的上涨来源\"，而且其阿尔茨海默氏症药物Leqembi的销售增长缓慢。** Needham称，与医生和医疗保健专家的调查显示，Leqembi的销售增长将 \"保持缓慢\"，并将2024年的预期下调了16%，降至约2.05亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","LLY"],"gpt_icon":1},{"id":"2483630089","title":"美国研究综述-应用材料公司、迪士尼、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2483630089","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483630089?lang=zh_cn&edition=full","pubTime":"2024-11-16 01:28","pubTimestamp":1731691712,"startTime":"0","endTime":"0","summary":"美国研究综述-应用材料公司、迪士尼、沃尔玛路透11月15日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括应用材料公司、迪士尼和沃尔玛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4T3MM1DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASB","BAC","AHCO","SCHW","AFG","AMAT","ARE","ASND","LNG","AIN","AESI","AKYA","ALGT","APH","BK4588","CABA","BIIB","LU1267930227.SGD","IE00BKVL7J92.USD","ASTS","CELC","BMY","IE00BBT3K403.USD","BK4534","AAP","ADSK","BL","ALK","BTM","LU1074936037.SGD","AGCO","AHR","AAL","BKR","LU1861217088.USD","BE","AROC","LU1032466523.USD","BRX","BV","ARI","BLUE","BJ","LU0354030511.USD","CHX","AMH","LU0868494708.USD","CAVA","AGYS","BRZE"],"gpt_icon":1},{"id":"2483868343","title":"BUZZ-欧盟监管机构推荐阿尔茨海默氏症药物后，百健公司股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868343","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483868343?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:23","pubTimestamp":1731601431,"startTime":"0","endTime":"0","summary":"11月14日 - ** 制药公司百健BIIB.O股价上涨2%至169.14美元** 欧盟药品监管机构表示，建议批准  卫材4523.T和百健公司的药物Leqembi用于早期阿尔茨海默病患者。** 7月份，药品监管机构否决了Leqembi ，称其严重脑肿胀的风险不足以抵消其对减缓认知能力衰退的微小影响。** 截至目前，百健公司股价下跌了34.3%。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4T3ML1MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4532","LU0109394709.USD","LU0320765992.SGD","BK4139","IE00B19Z9Z06.USD","IE00B894F039.SGD","BIIB","IE00B19Z9P08.USD","BK4588","BK4533","BK4585","LU0234570918.USD"],"gpt_icon":0},{"id":"2483385848","title":"欧盟药品监管机构推荐卫材-百健的阿尔茨海默氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385848","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483385848?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:07","pubTimestamp":1731600476,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透11月14日 - 欧盟药品监管机构周四表示，建议批准卫材  和百健  的Leqembi用于早期阿尔茨海默病患者的治疗，几个月前该机构首次拒绝了这种治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4533","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0889565916.HKD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0320765992.SGD","BIIB","LU0109394709.USD","BK4139","BK4532"],"gpt_icon":0},{"id":"2483385793","title":"渤健公司盘中异动 股价大涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385793","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483385793?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:03","pubTimestamp":1731600220,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日00时03分，渤健公司股票出现异动，股价快速拉升5.24%。截至发稿，该股报174.47美元/股，成交量79.4063万股，换手率0.54%，振幅6.05%。机构评级方面，在所有37家参与评级的机构中，65%的券商给予买入建议，35%的券商给予持有建议，无券商给予卖出建议。渤健公司股票所在的制药行业中，整体跌幅为0.97%。渤健公司公司简介：Biogen和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111500034098e42b0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111500034098e42b0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BIIB","BK4585","IE00B894F039.SGD","BK4532","LU0889565916.HKD","BK4588","LU0109394709.USD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0234570918.USD","LU0320765992.SGD","BK4533"],"gpt_icon":0},{"id":"2483050876","title":"美国研究综述-思科、Freshpet、Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050876","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483050876?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:06","pubTimestamp":1731585982,"startTime":"0","endTime":"0","summary":"美国研究综述-思科、Freshpet、Nvidia路透11月14日 - 华尔街证券分析师周四调整了对思科、Freshpet 和 Nvidia 等几家美国上市公司的评级和目标价。要闻 * 思科CSCO.O：杰富瑞将目标价从53美元上调至66美元 * Freshpet Inc FRPT.O：奥本海默将目标价从155美元上调至180美元  * ICU Medical Inc ICUI.O：Raymond James将目标价从190美元上调至205美元  * Kronos Bio Inc KRON.O：TD Cowen将目标价从买入下调至持有 * Nvidia Corp NVDA.O：奥本海默将目标价从 150 美元上调至 175 美元 以下是路透周四报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4T3ML18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","SPRY","BRBR","BK4209","APD","CAVA","ACRV","LU2106854487.HKD","ALMS","CHGG","LU1244550577.SGD","AESI","CPAY","ALLO","CSCO","AZTA","BTMD","CPT","CRVS","BPMC","CAKE","BIIB","LU1244550494.USD","EE","LU0868494708.USD","AIT","IE00BZ1G4Q59.USD","AROC","CPB","CBSH","LU0300736492.USD","AMGN","ADAP","AVB","CTRA","CHX","IE00BFXG1179.USD","AXTA","BWXT","CNNE","COGT","APEI","BKR","FDMT","SG9999002232.USD","DOX","LU1894683348.USD","ALSN","BK4550","LU0234572021.USD"],"gpt_icon":0},{"id":"2481167540","title":"渤健公司2024财年第三财季实现净利润3.89亿美元，同比增加671.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481167540","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481167540?lang=zh_cn&edition=full","pubTime":"2024-11-08 00:00","pubTimestamp":1730995233,"startTime":"0","endTime":"0","summary":"11月8日，渤健公司公布财报，公告显示公司2024财年第三财季净利润为3.89亿美元，同比增加671.22%；其中营业收入为23.76亿美元，同比减少2.42%，每股基本收益为2.67美元。从资产负债表来看，渤健公司总负债119.54亿美元，其中短期债务17.48亿美元，资产负债比为2.37，流动比率为1.26。机构评级：截至2024年11月8日，当前有27家机构对渤健公司目标价做出预测，其中目标均价为254.56美元，其中最低目标价为180.00美元，最高目标价为342.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000045abaaa06a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000045abaaa06a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB"],"gpt_icon":0},{"id":"2480083599","title":"实时市场-脑力劳动正在进行，但神经药物开发人员仍需努力","url":"https://stock-news.laohu8.com/highlight/detail?id=2480083599","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480083599?lang=zh_cn&edition=full","pubTime":"2024-11-01 23:38","pubTimestamp":1730475534,"startTime":"0","endTime":"0","summary":"您可以通过以下网址与我们分享您的想法  脑力劳动正在进行，但神经药物开发商仍有很长的路要走Canaccord Genuity分析师周五表示，神经系统疾病方面的需求尚未得到满足，这激起了人们对正在开发的治疗抑郁症、阿尔茨海默病和痴呆症等神经系统疾病药物试验数据的期待，这些疾病影响着全球数百万患者。嘉能可补充说，尽管在理解阿尔茨海默氏症这种神经退行性疾病方面还存在挑战，但 Leqembi 和 Kisunla 的成功已经到来。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","DDM","QLD","LU0122379950.USD","BK4581","CRVO",".DJI","LU0234570918.USD","LU1064131342.USD","QID","BIIB","PSQ","SQQQ","LU0708995401.HKD","LU0320765646.SGD","SDOW","LU0417517546.SGD","IE00B19Z9Z06.USD","BK4504","LU0097036916.USD","LU0943347566.SGD","DXD",".IXIC","IE00BJJMRZ35.SGD","NMRA","LU0203347892.USD","DJX","LU0795875086.SGD","LU0354030511.USD","BK4532","IE0034235303.USD","BK4139","UDOW","LU0203201768.USD","MNQmain",".SPX","LU0094547139.USD","LU0096364046.USD","TQQQ","DOG","IE00B42XCP33.USD","BMY","LU0456855351.SGD","NQmain","JNJ","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1066051225.USD"],"gpt_icon":1},{"id":"2479942039","title":"美国研究综述-Altair 工程公司、布林克国际公司、梅塔公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2479942039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479942039?lang=zh_cn&edition=full","pubTime":"2024-10-31 22:41","pubTimestamp":1730385704,"startTime":"0","endTime":"0","summary":"    路透10月31日 - 华尔街证券分析师周四调整了对Altair Engineering、Brinker International和Meta等几家美国上市公司的评级和目标价。要闻 * Altair Engineering Inc   ：尼德姆将其评级从 \"买入 \"下调至 \"持有 * Blackbaud Inc   ：贝雅将其评级从 \"跑赢大盘 \"下调至 \"中性\"。* Brinker International Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。* Meta   ：贝尔德将目标价从605美元上调至630美元 以下是路透周四报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","BPMC","AUR","IE00BFXG0V08.USD","CAT","AX","CHRW","BLKB","ABBV","AVDL","CDW","ARVN","ALMS","META","ADP","ATNI","BRO","BL","ANSS","CWH","BK4141","EAT","ATEC","BMRC","ALTR","AXTA","ALRS","ARCC","BIIB","LU1854104046.USD","BK4140","ALHC","BIO","BKNG","IE00BZ199S13.USD","ALKT","IE0009354923.USD","BG","LU2264538146.SGD","AVT","ATI","LU0061474960.USD","LU1169589451.USD","TECH","IE00BMPRXR70.SGD","ALL","IE00BMPRXN33.USD"],"gpt_icon":1},{"id":"2479722217","title":"美国研究综述-全州保险公司、布林克国际公司、梅塔公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2479722217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479722217?lang=zh_cn&edition=full","pubTime":"2024-10-31 15:30","pubTimestamp":1730359839,"startTime":"0","endTime":"0","summary":"    路透10月31日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Allstate、Brinker International 和 Meta。要闻 * 全州公司  ：摩根大通将目标价从207美元上调至217美元             * Blackbaud Inc   ：贝雅将其评级从 \"跑赢大盘 \"下调至 \"中性\"。* Meta   ：贝尔德将目标价从605美元上调至630美元 以下是路透周四报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRTC","FSBC","RIOT","EAT","ECL","HTLF","ILMN","LU0882574055.USD","CRK","LU2023250504.SGD","IE00B19Z4B17.USD","SKY","ITCI","BK4130","HLI","CLX","LU1059921491.USD","ALKT","ADP","BIDU","GRAB","LU1064131342.USD","LU0708994859.HKD","IE00B19Z6F94.USD","EQT","GEHC","BKNG","KHC","PDD","AFRM","BLKB","BRO","CTSH","COIN","MSTR","LU2125910336.SGD","ALL","CDW","BIO","DASH","CRWD","BIIB","LU0354030438.USD","NVDA","ALRS","SOFI","JKHY","LU0106261372.USD","ABBV","EBAY","FND","RIVN","DHI","ATI","CAT","BMRC","HUBG","BABA","IE00BYQQ9H92.USD","CFLT"],"gpt_icon":1},{"id":"2479748826","title":"渤健(BIIB.US)达成14.5亿美元小分子降解剂合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2479748826","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479748826?lang=zh_cn&edition=full","pubTime":"2024-10-31 11:27","pubTimestamp":1730345248,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，日前，渤健和Neomorph宣布开展一项研究合作，旨在发现和开发分子胶降解剂用于治疗阿尔茨海默病、罕见神经系统和免疫系统疾病等疾病。根据协议条款，渤健和Neomorph将合作识别、验证和优化多个分子胶降解剂，这些降解剂靶向高优先级别的靶点。Neomorph将获得预付款，并有资格在当每个靶标进入合作各个阶段时获得里程碑款项，包括近期的某些临床前里程碑以及某些临床、监管、商业和销售里程碑，总款项可高达14.5亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB","BK4532","BK4588","LU0234570918.USD","IE00B19Z9P08.USD","BK4533","BK4585","LU0320765992.SGD","IE00B19Z9Z06.USD","LU0889565916.HKD","LU0109394709.USD","IE00B894F039.SGD","BK4139"],"gpt_icon":0},{"id":"2479207884","title":"阿尔茨海默症药物出现增长迹象 百健(BIIB.US)上调全年盈利指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2479207884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479207884?lang=zh_cn&edition=full","pubTime":"2024-10-30 20:55","pubTimestamp":1730292900,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，受持续的成本削减措施和新型阿尔茨海默病治疗药物的强劲表现推动，百健公布第三季度销售额和利润好于预期，还上调了年度盈利预期。今年 5 月，百健同意以高达 18 亿美元的价格收购Human Immunology Biosciences Inc.，以扩大其免疫疾病治疗产品线。百健希望 Leqembi 能够帮助抵消其多发性硬化症药物销量下滑的影响。今年 7 月，美国监管机构批准了礼来公司的一种阿尔茨海默病治疗药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z9P08.USD","IE00B894F039.SGD","BK4588","IE00B19Z9Z06.USD","LU0109394709.USD","BK4585","BIIB","LU0320765992.SGD","LU0889565916.HKD","BK4533","BK4139","BK4532","LU0234570918.USD"],"gpt_icon":0},{"id":"2479670735","title":"更新版 2-百健公司上调年度盈利预期，新疗法提振盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2479670735","media":"路透中文","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479670735?lang=zh_cn&edition=full","pubTime":"2024-10-30 20:14","pubTimestamp":1730290480,"startTime":"0","endTime":"0","summary":"更新版 2-百健公司上调年度盈利预期，新疗法提振盈利更新股价，在第 4 段中添加分析师评论，在第 7 段中添加首席执行官评论及图表Mariam Sunny. Biogen BIIB.O周三上调了年度利润预期，原因是新疗法和成本削减措施抵消了其多发性硬化症药物销售额的下降。百健公司预计年度调整后每股利润为16.10-16 .60美元，而此前的 预期区间为每股 15.75- 16.25美元。该公司 公布的调整后每股利润为 4.08 美元，高于预期的每股 3.79 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nL4T3M61IA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"更新版 2-百健公司上调年度盈利预期，新疗法提振盈利","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4139","LU0320765992.SGD","BK4585","BK4532","LU0889565916.HKD","BK4588","LU0109394709.USD","BIIB","IE00B19Z9Z06.USD","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2479201895","title":"更新版 1-百健上调年度盈利预期，新疗法提振盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2479201895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479201895?lang=zh_cn&edition=full","pubTime":"2024-10-30 20:14","pubTimestamp":1730290480,"startTime":"0","endTime":"0","summary":"     路透10月30日 -    Biogen   周三上调了年度利润预期，第三季度利润超出预期，原因是新疗法和成本削减帮助弥补了其多发性硬化症药物销售的下滑。该公司将希望寄托在新推出的治疗药物上，包括Leqembi，该药物在美国的销售回升缓慢，因为成本、疗效和副作用等问题备受关注。百健公司目前预计年度调整后利润为每股16.10美元至16.60美元，而之前的 预测为每股15.75美元至16.25美元。该公司公布的调整后利润为每股 4.08 美元，高于预期的每股 3.79 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU0320765992.SGD","LU0889565916.HKD","BK4533","IE00B894F039.SGD","BK4588","BIIB","BK4532","BK4139","BK4585","LU0109394709.USD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"2479029203","title":"渤健公司(BIIB)盘前涨1.24% 第三季度扭亏为盈3.89亿美元 营收超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479029203","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479029203?lang=zh_cn&edition=full","pubTime":"2024-10-30 19:25","pubTimestamp":1730287520,"startTime":"0","endTime":"0","summary":"金吾财讯 | 渤健公司(BIIB)盘前股价走高，暂涨1.24%，报185.75美元。公司于第三季度净利润录得3.89亿美元，去年亏损6800万美元，预期4.35亿美元；营收录得24.6亿美元，超过预期的24.3亿美元；每股收益2.66美元，预期2.92美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/ZjE4MDdhNTRkYTVhY2QzODgyOWQwYzcxZDQ3NTA3Njg3NjgwMzk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZjE4MDdhNTRkYTVhY2QzODgyOWQwYzcxZDQ3NTA3Njg3NjgwMzk=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"281437","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"gpt_icon":0},{"id":"2479027269","title":"成本削减助力百健公司上调年度利润预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479027269","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479027269?lang=zh_cn&edition=full","pubTime":"2024-10-30 18:45","pubTimestamp":1730285103,"startTime":"0","endTime":"0","summary":"截至9月30日的第三季度，该公司与卫材  合作销售的Leqembi在美国的销售额为3900万美元。百健现在预计年度调整后每股利润在16.10美元到16.60美元之间，而之前的预测在15.75美元到16.25美元之间。该公司公布的第三季度调整后利润为每股 4.08 美元，高于预期的每股 3.79 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE00B19Z9P08.USD","BIIB","BK4139","LU0320765992.SGD","LU0109394709.USD","IE00B19Z9Z06.USD","LU0234570918.USD","LU0889565916.HKD","BK4533","BK4585","IE00B894F039.SGD","BK4588"],"gpt_icon":0},{"id":"2479423806","title":"研究发现，逐步服用礼来阿尔茨海默氏症药物可降低脑肿胀风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2479423806","media":"路透中文","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479423806?lang=zh_cn&edition=full","pubTime":"2024-10-29 23:58","pubTimestamp":1730217530,"startTime":"0","endTime":"0","summary":"路透芝加哥10月29日 - 周二在一次医学会议上公布的一项晚期试验的中期结果显示，礼来公司的LLY.N阿尔茨海默氏症药物Kisunla开始采用更渐进的给药时间表后，出现潜在严重脑肿胀的患者比例有所下降。在这项为期一年的研究进行到第24周时，在接受较低起始剂量每月输注的早期阿尔茨海默氏症患者中，有14%的患者出现了被称为ARIA-E的脑肿胀副作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nL4T3M525V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","LU0320765059.SGD","LU1093756168.USD","LU0238689110.USD","IE00B19Z9Z06.USD","LU0114720955.EUR","BIIB","IE00B2B36J28.USD","LU0109391861.USD","LU0882574055.USD","LU0471298777.SGD","BK4533","LU0820561909.HKD","LU0234570918.USD","LU1057294990.SGD","LU1035775433.USD","BK4588","LU0256863902.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0466842654.USD","BK4534","LU0943347566.SGD","LU0708995401.HKD","IE00BJLML261.HKD","LU0640476718.USD","IE00BJJMRZ35.SGD","LU0689472784.USD","BK4585","BK4581","LU0058720904.USD","LU0456855351.SGD","LU0109394709.USD","IE00B1BXHZ80.USD","IE0004445239.USD","LU0106261372.USD","LU0354030511.USD","LU0823416689.USD","LU0006306889.USD","LU0256863811.USD","LU0198837287.USD","LU1064131342.USD","LU0882574139.USD","IE00BFTCPJ56.SGD","LU0203202063.USD","LU0820561818.USD","IE00B19Z9P08.USD","LU0094547139.USD","IE0002141913.USD","LU0417517546.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0417},{"period":"1month","weight":-0.15},{"period":"3month","weight":-0.2292},{"period":"6month","weight":-0.2746},{"period":"1year","weight":-0.3167},{"period":"ytd","weight":-0.3894}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，他们收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.042714},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.004267},{"month":3,"riseRate":0.515152,"avgChangeRate":-0.023197},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.018344},{"month":5,"riseRate":0.606061,"avgChangeRate":0.032222},{"month":6,"riseRate":0.484848,"avgChangeRate":0.01808},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035186},{"month":8,"riseRate":0.575758,"avgChangeRate":0.030603},{"month":9,"riseRate":0.484848,"avgChangeRate":0.022099},{"month":10,"riseRate":0.529412,"avgChangeRate":0.057649},{"month":11,"riseRate":0.588235,"avgChangeRate":0.012975},{"month":12,"riseRate":0.484848,"avgChangeRate":0.038726}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}